Podcasts about hematological malignancies

Scientific discovery happens in the lab—but it starts with curiosity and determination. In this episode of Absolute Gene-ius, we welcome Valeria Rangel, a PhD candidate at the University of California Irvine, who shares her research on acute lymphoblastic leukemia and the innovative ways digital PCR is helping uncover genetic patterns linked to cancer in Hispanic populations.Val's work focuses on Philadelphia chromosome-like (Ph-like) B-cell acute lymphoblastic leukemia, a rare and aggressive form of cancer. She explains how her lab uses digital PCR to detect mutations with high precision, identify risk factors in certain populations, and even validate findings using CRISPR-Cas9 gene editing. Through her research, Val sheds light on the role of SNPs, methylation patterns, and translocations in leukemia progression—demonstrating how digital PCR is transforming the way we approach cancer research.Beyond the science, Val takes us on her personal journey, from struggling to break into research due to financial barriers to finding her passion in oncology. In this episode's Career Corner, she shares valuable advice for aspiring scientists, tips for landing research opportunities, and some of her most hilarious and humbling lab moments (yes, she has broken multiple pipettes).Visit the Absolute Gene-ius pageto learn more about the guests, the hosts, and the Applied Biosystems QuantStudio Absolute Q Digital PCR System. 

Send us a textTreating patients with hematologic oncologic diagnoses isn't just about managing fatigue—it's about understanding the complex, ever-changing challenges they face at every stage of treatment. From acute inpatient deficits to long-term survivorship, physical therapists play a critical role in improving outcomes for this population.In this episode, I sit down with Dr. Shai Sewell, PT, & Scott Capozza, PT, to break down what PTs really need to know about hematologic cancers to start treating these patients. We cover the basics of hematological malignancies, differences in treatment between heme-onc & other tumors, and navigating biggest rehab challenges throughout the transplant process. If you're working with—or want to work with—this complex patient population, this episode is a must-listen!

A new research perspective was published in Oncotarget's Volume 14 on August 7, 2023, entitled, “CDK9 INHIBITORS: a promising combination partner in the treatment of hematological malignancies.” In their new perspective, researchers Daniel Morillo, Gala Vega and Victor Moreno from Hospital Fundación Jiménez Díaz discuss Cyclin-dependent kinases (CDK) in hematological malignancies. CDKs belong to a family of serine/threonine kinases that need to form heterodimeric complexes with cyclins to perform their functions. These kinases are involved in multiple processes within cells, including cell cycle, apoptosis, transcription and differentiation. These kinases are often overexpressed in different malignancies, making them potential targets for new drugs. Most hematological malignancies are characterized by overexpression of certain cancer promoting genes, such as MYC, MCL1 and cyclin D1. Preclinical studies in animal models have shown that CDK9 inhibitors suppress the transcription of these anti-apoptotic and pro-survival proteins, and suggest their potential synergism with other drugs. In its first in-human trial, enitociclib demonstrated clinical activity in a small cohort of patients with high grade B lymphoma with MYC and BCL2 and/or BCL6 rearrangements, inducing complete responses in 2 of 7 subjects (29%) in monotherapy. “In summary, most hematological malignancies are characterized by overexpression of certain cancer promoting genes, such as MYC and MCL1. CDK9 inhibitors are relatively new drugs that inhibit transcription of these anti-apoptotic and pro-survival proteins.” DOI - https://doi.org/10.18632/oncotarget.28473 Correspondence to - Victor Moreno - victor.moreno@startmadrid.com Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.28473 Subscribe for free publication alerts from Oncotarget - https://www.oncotarget.com/subscribe/ Keywords - cancer, cyclin-dependent kinases (CDK), CDK9, hematological malignancies About Oncotarget Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science. To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us: SoundCloud - https://soundcloud.com/oncotarget Facebook - https://www.facebook.com/Oncotarget/ Twitter - https://twitter.com/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/@OncotargetJournal LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Media Contact MEDIA@IMPACTJOURNALS.COM 18009220957

Visit https://i3health.com/relapsed-refractory-multiple-myeloma to book a live or virtual meeting at your own institution and hear more expert perspectives from Dr. Kumar or other esteemed multiple myeloma faculty! Currently, Dr. Shaji Kumar, Professor of Hematological Malignancies at the Mayo Clinic Cancer Center, is the chair of Optimizing Treatment Sequencing for Patients With Relapsed/Refractory Multiple Myeloma, a continuing medical education/nursing continuing professional development (CME/NCPD)–accredited live or virtual meeting series provided by i3 Health. In this interview, Dr. Kumar provides a glimpse into the exciting developments in multiple myeloma research that are covered in the program, including breaking updates from the 2022 American Society of Hematology (ASH) Annual Meeting.

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Ehab L. Atallah, MD New longer-term outcome data for chronic lymphocytic leukemia (CLL) has recently emerged with some interesting results. To dive into the key findings of these trials and other current CLL treatments available, Dr. Charles Turck is joined by Dr. Ehan Atallah, Professor of Medicine and the Section Head of Hematological Malignancies at the Medical College of Wisconsin Division of Hematology and Oncology.

Two of the co-authors (Dr Jameel Abdulrehman and Dr Leslie Skeith) of the recently published review and meta-analysis, "Recurrence after stopping anticoagulants in women with combined oral contraceptive-associated venous thromboembolism: A systematic review and meta-analysis" (https://doi.org/10.1111/bjh.18331) discuss the clinical relevance of the results and implications for managing risk for women who have experienced a VTE while on combined oral contraceptives. Dr. Jameel Abdulrehman is a Hematologist and clinician investigator with specialization in Thrombosis and Hemostasis at the Toronto General Hospital within the University Health Network and assistant professor at the University of Toronto. He completed medical school at the University of Alberta, Internal Medicine residency at Western University, Hematology residency at the University of Alberta, a fellowship in thrombosis and hemostasis at the University of Toronto, and a masters in clinical epidemiology at McMaster University. He is an early career investigator with research interests in clinical studies in the use anticoagulation in special populations. He is also the regular co-host of this podcast. And Dr Leslie Skeith:Dr. Leslie Skeith is a Associate Professor in the Division of Hematology & Hematological Malignancies at the University of Calgary. She completed her medical school and Hematology residency training at the University of Calgary, and completed a 2-year fellowship in Thrombosis Medicine at the University of Ottawa. Dr. Skeith's research interest is in the area of pregnancy and venous thromboembolism, as well as medical education. She is currently completing a Master of Health Professions Education (MHPE) degree at the University of Chicago at Illinois (UIC).Follow us:@thrombosiscan@leslieskeithReference:Abdulrehman J, Elbaz C,Aziz D, Parpia S, Fazelzad R, Eischer L, et al. Recurrence after stopping anticoagulants in women with combined oral contraceptive-associated venous thromboembolism: A systematic review and metaanalysis. Br J Haematol. 2022;00:1–13. https://doi.org/10.1111/bjh.18331Support the showhttps://thrombosiscanada.caTake a look at our healthcare professional and patient resources, videos and publications on thrombosis from the expert members of Thrombosis Canada

Welcome to IMPACT Medicom's podcast series on COVID-19 prophylaxis. In this second episode of the series, we discuss the use of COVID-19 pre-exposure prophylaxis as a strategy to protect patients with hematological malignancies who are not able to mount a sufficient antibody response to vaccination.  Our Guest:Our guest  is Dr Laurie Sehn, Clinical Assistant Professor in the Department of Medicine at the University of British Columbia and Medical Oncologist at BC Cancer in Vancouver, British Columbia. Sponsored by AstraZeneca CanadaIf you enjoy our podcast, please review and subscribe. For more podcasts and other medical education content, visit our website at: https://www.impactmedicom.com 

Apresentação: Cláudia Inhaia Instagram @cinhaia Twitter cinhaia Sabrina Corrêa da Costa Ribeiro Instagram @papopaliativo Twitter Uti.Correa Convidadas: Amanda Pifano Instagram @mandinhapifano CHAMADA O paciente com doença hematológica, tanto benigna como maligna, pode apresentar grande carga de sofrimento e frequentemente é submetido a tratamentos agressivos com muitos efeitos colaterais. A abordagem de Cuidado Paliativo em conjunto com o tratamento da doença hematológica é recomendada atualmente, com base em estudos que demonstraram melhora de sintomas e redução da incidência de depressão e ansiedade. Neste episódio, as médicas Claudia Inhaia e Sabrina Ribeiro recebem Amanda Pifano, Médica hematologista e paliativista, Mestre pela Faculdade de Medicina da Universidade de São Paulo, que irá discutir como esta integração se dá na prática e como o cuidado paliativo pode impactar positivamente a qualidade de vida destes pacientes. Informamos que as opiniões dos entrevistados não necessariamente reflete a opinião da ANCP. REFERÊNCIAS CITADAS NO EPISÓDIO 1- Ruiz M, Reynolds P, Marranzini R, Khan A, Ketterer J, Brahim A. Role of Early Palliative Care Interventions in Hematological Malignancies and Bone Marrow Transplant Patients: Barriers and Potential Solutions. Am J Hosp Palliat Care. 2018 Nov;35(11):1456-1460. doi: 10.1177/1049909118772849. Epub 2018 Apr 26. PMID: 29699418. 2- Mitchell SA. Palliative care during and following allogeneic hematopoietic stem cell transplantation. Curr Opin Support Palliat Care. 2018;12(1):58-64. doi:10.1097/SPC.0000000000000327 3- Wilkie DJ, Johnson B, Mack AK, Labotka R, Molokie RE. Sickle cell disease: an opportunity for palliative care across the life span. Nurs Clin North Am. 2010;45(3):375-397. doi:10.1016/j.cnur.2010.03.003 DIRECIONAMENTO METADADOS #ANCPaliativos #CuidadosPaliativos #PalliativeCare #Saude #ProfissionaisDeSaude #EquipeMultidisciplinar #CongressoPaliativo22 #Paliativo22 #Omelhorcuidadoparatodosavidatoda #conforto #autonomia #objetivodecuidado #bioetica #bioethics #decisaocompartilhada #hematologia #quimioterapia #controledesintomas #imunoterapia #terapiacelular #TMO #diretivasantecipadas #depressão #ansiedade #abbh

In this podcast series on pre- and post- COVID-19 prophylaxis, we discuss immunization against COVID-19 and how we can protect our most vulnerable populations who are not able to mount a sufficient antibody response to vaccination. In this fourth episode of the series, we discuss:Response to COVID-19 vaccines in the general populationResponse to COVID-19 vaccines in immunocompromised peopleThe impact of COVID-19 on patients with hematologic malignanciesThe potential role of pre- and post- COVID-19 exposure prophylaxis for people with hematologic malignanciesOur Guest:Our guest on today's episode is Dr. Carolyn Owen, who is an an Associate Professor in the Division of Hematology & Hematological Malignancies at the University of Calgary. This podcast episode was sponsored by AstraZeneca Canada.If you enjoy our podcast, please review and subscribe. For more podcasts and other medical education content, visit our website at: https://www.impactmedicom.com

In the fifth and final episode of the Aging Patient: Dispelling Myths podcast series, host Gareth Tucker and guest experts Prof Raul Cordoba, Dr Ulrich Wedding, and Dr Dominique Bron discuss the ethical issues associated with treating hematological malignancies in older adults. They raise different points regarding treatment decisions made with (and not without) the patient and amongst other parameters, how much of an impact costs have in the choice of treatment. Dr Bron also reminds us of the 4 principles of healthcare (nonmaleficence, beneficence, autonomy, and justice) – and that age is not a criterion in deciding whether a patient should be treated or not. Finally, they address the impact of COVID-19 on the current clinical practice and whether it has exacerbated ethical issues. Host: Gareth Tucker; Guest: Prof Raul Cordoba, Dr Ulrich Wedding, Prof Dominique Bron In the second episode of the Aging Patient: Dispelling Myths podcast series, the importance of medical decision making based on a patient's ‘fitness' rather than their age will be stressed, and the impact of good diet and exercise in maintaining fitness and delaying sarcopenia highlighted. Host: Gareth Tucker; Guest: Prof Alessandra Tucci, Prof Sergio Storti What did you think of this podcast? Share your opinions with us in this short feedback survey. https://forms.monday.com/forms/d02e52896815eef59ecae09fb74dd78f?r=use1 (Provide Feedback) Would you like to receive EBAH CME credit points for listening to this podcast? Please visit the EHA Campus and finalize the quiz questions in the Aging Patient: Dispelling Myths program. https://ehacampus.ehaweb.org/ (https://ehaedu.org/Campus) Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to. Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/?utm_medium=podcast&utm_source=bcast&utm_campaign=eha-unplugged (https://www.instagram.com/EHA_Hematology/) Facebook: https://e-h-a.link/facebook?utm_medium=podcast&utm_source=bcast&utm_campaign=eha-unplugged (https://e-h-a.link/facebook) LinkedIn: https://www.linkedin.com/company/eha/?utm_medium=podcast&utm_source=bcast&utm_campaign=eha-unplugged (https://www.linkedin.com/company/eha/) Email us: education@ehaweb.org Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe?utm_medium=podcast&utm_source=bcast&utm_campaign=eha-unplugged (https://eha.news/subscribe) 

In the third episode of the Aging Patient: Dispelling Myths podcast series, host Gareth Tucker and experts Prof Antonio Almeida, Prof Valentin Goede, and Dr Annamaria Brioli discuss the treatment of hematological malignancies in older adults, involving polypharmacy in most cases. They describe how patients commonly react to polypharmacy and how challenging it can be to have all the information about a patient's full list of medication, and to keep them compliant. They also address the step of deprescribing, a critical point in the therapy of these patients. Host: Gareth Tucker; Guest: Prof Valentin Goede, Prof Antonio Almeida, Dr Annamaria Brioli What did you think of this podcast? Share your opinions with us in this short feedback survey. https://forms.monday.com/forms/d02e52896815eef59ecae09fb74dd78f?r=use1 (Provide Feedback) Would you like to receive EBAH CME credit points for listening to this podcast? Please visit the EHA Campus and finalize the quiz questions in the Aging Patient: Dispelling Myths program. https://ehacampus.ehaweb.org/ (https://ehaedu.org/Campus) Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to. Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/?utm_medium=podcast&utm_source=bcast&utm_campaign=eha-unplugged (https://www.instagram.com/EHA_Hematology/) Facebook: https://e-h-a.link/facebook?utm_medium=podcast&utm_source=bcast&utm_campaign=eha-unplugged (https://e-h-a.link/facebook) LinkedIn: https://www.linkedin.com/company/eha/?utm_medium=podcast&utm_source=bcast&utm_campaign=eha-unplugged (https://www.linkedin.com/company/eha/) Email us: education@ehaweb.org Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe?utm_medium=podcast&utm_source=bcast&utm_campaign=eha-unplugged (https://eha.news/subscribe) 

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Elizabeth A. Brem, MD Guest: Ehab L. Atallah, MD Dr. Elizabeth Brém, an Assistant Professor in the Division of Hematology/Oncology at the University of California Irvine School of Medicine and Dr. Ehab Atallah, a Professor of Medicine and Section Head of Hematological Malignancies in the Medical College of Wisconsin's Division of Hematology and Oncology join Dr. Charles Turck to explore collaborative approaches and share best practices in the management of chronic lymphocytic leukemia.

In this episode of our podcast, we discuss the use of zanubrutinib for the treatment of Waldenstrom's Macroglobulinemia.  Our episode discusses data from the Phase 3 ASPEN trial, comparing the efficacy and safety of zanubrutinib with ibrutinib in these patients. Our GuestsOur first guest, Dr. Constantine Tam, is a Professor of Hematology at the University of Melbourne, and Consultant Hematologist at the Peter MacCallum Cancer Centre in Melbourne, Australia. He is also the lead author on the ASPEN trial, and provides a detailed look at the key data from this study.  We are then joined by Dr. Carolyn Owen, an Associate Professor in the Division of Hematology & Hematological Malignancies at the University of Calgary. Dr. Owen discusses the potential impact of the data from the ASPEN trial on Canadian clinical practice. And how zanubrutinib may fit into the Canadian treatment algorithm for Waldenstrom's Macroglobulinemia. This podcast episode was sponsored by Beigene Canada.If you enjoy our podcast, please review and subscribe. For more podcasts and other medical education content, visit our website at: https://www.impactmedicom.com 

Describe how cell therapy was developed for heme malignancies.Identify which types of cell products have been evaluated in clinical studies.Discuss challenges & opportunities in developing cell therapies for heme malignancies.

Dr. Susanta Kumar Paikaray is a medical oncologist, with a special interest in hematological malignancies, and breast cancer. He joins in conversation with Zenonco.io to share more about hematological malignancies and their treatments, colorectal cancer, breast cancer, and pediatric cancer. Zenonco.io - Making quality integrative oncology cancer care accessible to all. Visit our Official website: https://zenonco.io/ If you or your loved one has been diagnosed with cancer recently, and need guidance on treatment or have any doubts or queries, please call ZenOnco.io on +91 99 30 70 90 00.

In this episode, we discuss the use of Bruton's Tyrosine Kinase (BTK) inhibitors for the treatment of patients with chronic lymphocytic leukemia (CLL). Included is a discussion of:Novel treatments for CLLThe impact of BTK inhibitors for the treatment of CLLThe differences between first- (e.g. ibrutinib) and second-generation (e.g. acalabrutinib, zanubrutinib, tirabrutinib) BTK inhibitorsPreliminary results from the ELEVATE-RR trial comparing the efficacy and safety of acalabrutinib vs ibrutinib in high-risk relapsed/refractory CLL (see: https://www.cancernetwork.com/view/acalabrutinib-meets-primary-end-point-versus-ibrutinib-in-previously-treated-high-risk-cll for the full press release)Our guest:Dr. Carolyn Owen is an Associate Professor in the Division of Hematology & Hematological Malignancies at the University of Calgary. She completed her internal medicine training in Ottawa, followed by Hematology training in Vancouver and a research fellowship in molecular genetics at Barts and the London School of Medicine. Her current clinical interests are in the areas of low-grade lymphoma and chronic lymphocytic leukemia (or CLL) and she is the local principal investigator at the Tom Baker Cancer Centre for a number of clinical trials focusing on these areas. Funding for this episode provided by AstraZeneca, Canada. If you in enjoy our podcast, please review and subscribe. For more podcasts, papers, and medical education programs, visit our website at: http://www.impactmedicom.com.

The Society of Hematologic Oncology (SOHO) 2020 Virtual Annual Meeting brought together global leading experts in hematological oncology who updated... The post SOHO 2020: Next questions in hematological malignancies appeared first on VJHemOnc.

The Society of Hematologic Oncology (SOHO) 2020 Virtual Annual Meeting brought together global leading experts in hematological oncology who updated... The post SOHO 2020: Next questions in hematological malignancies appeared first on VJHemOnc.

The ongoing COVID-19 pandemic caused by SARS-CoV-2 is an international public health issue and patients with cancer consistently demonstrate poorer... The post The HemOnc & COVID-19 Sessions: treating hematological malignancies, reducing nosocomial COVID-19 infections, clinical trial participation and resource allocation appeared first on VJHemOnc.

The ongoing COVID-19 pandemic caused by SARS-CoV-2 is an international public health issue and patients with cancer consistently demonstrate poorer... The post The HemOnc & COVID-19 Sessions: treating hematological malignancies, reducing nosocomial COVID-19 infections, clinical trial participation and resource allocation appeared first on VJHemOnc.

Cancer cells, explains Dorothy Sipkins, MD, PhD, “have this tendency to steal from or copy the way that normal cells respond to their microenvironment.” In this conversation Dr. Sipkins explains how cancer cells profit from the tissue microenvironment. She also describes an important discovery made by her lab, showing how acute lymphoblastic leukemia (ALL) cells get around the blood-brain barrier to find the microenvironment in the central nervous system where they flourish. Dorothy Sipkins, MD, PhD, is an associate professor at the Duke University Medical Center in the Division of Hematological Malignancies and Cellular Therapy. Dr. Sipkins runs a lab that’s focused on tissue microenvironments, or “niches, that regulate the migration, survival and regeneration of cancerous cells.” 3:42 – Why the tissue microenvironment is so important… 8:02 – …and how different microenvironments are crucial for cancer cells 11:55 –The treatment challenges resulting from the movement of acute lymphoblastic leukemia (ALL) cells into the central nervous system 16:17 – The long, difficult (but absolutely critical) journey her lab took to understanding how ALL gets around the blood-brain barrier to find the tissue microenvironment that allows it to flourish 30:36 – How her lab is trying to find “the best drug, the best tool, the best way to inhibit this process” in patients 31:07 – How ACS helped advance her research 32:52 – A message she’d like to share with survivors and caregivers

Part II: Advancements in Hematological Malignancies with guest Dr. Scott Huntington August 22, 2016 Yale Cancer Center visit: http://www.yalecancercenter.org email: canceranswers@yale.edu call: 203-785-4095

Part II: Advancements in Hematological Malignancies with guest Dr. Scott Huntington August 22, 2016 Yale Cancer Center visit: http://www.yalecancercenter.org email: canceranswers@yale.edu call: 203-785-4095

Advancements in Hematological Malignancies with guest Dr. Scott Huntington August 4, 2016 Yale Cancer Center visit: http://www.yalecancercenter.org email: canceranswers@yale.edu call: 203-785-4095

Advancements in Hematological Malignancies with guest Dr. Scott Huntington August 4, 2016 Yale Cancer Center visit: http://www.yalecancercenter.org email: canceranswers@yale.edu call: 203-785-4095

Interview with Simon Stanworth, from United Kingdom. Prof. Stanworth discusses the topic 'To do or not to do? Red cells and platelet transfusion in hematological malignancies'.The interview is led by Shaun McCann, Chair of EHATol Unit, Member of EHA Education Committee.

Interview with Simon Stanworth, from United Kingdom. Prof. Stanworth discusses the topic 'To do or not to do? Red cells and platelet transfusion in hematological malignancies'.The interview is led by Shaun McCann, Chair of EHATol Unit, Member of EHA Education Committee.

Join us as we talk with Dr. ParameswaranHari, MD, MRCP, MS, about transplants, his latest myeloma research and open clinical trials. Dr. Hari is the Armand Quick-William Stapp Professor of Hematology, Section Head of Hematological Malignancies and the Director of the Adult Blood and Marrow Transplant Program at the Medical College of Wisconsin.

Join us as we talk with Dr. ParameswaranHari, MD, MRCP, MS, about transplants, his latest myeloma research and open clinical trials. Dr. Hari is the Armand Quick-William Stapp Professor of Hematology, Section Head of Hematological Malignancies and the Director of the Adult Blood and Marrow Transplant Program at the Medical College of Wisconsin.

Guest: Ruben Mesa, MD, FACP, MPN Expert Host: Bruce Bloom, DDS, JD On location from the Mayo Clinic's 5th State of the Art Symposium on Hematological Malignancies in Phoenix, AZ, host Dr. Bruce Bloom discusses the goals and highlights of the conference with its co-director, Dr. Ruben Mesa, a hematologist, medical oncologist, and associate professor of medicine at the Mayo Clinic in Scottsdale, AZ.